Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) shot up 5.9% on Thursday after Jonestrading raised their price target on the stock from $22.00 to $26.00. Jonestrading currently has a buy rating on the stock. Cullinan Oncology traded as high as $19.14 and last traded at $18.94. 60,437 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 450,834 shares. The stock had previously closed at $17.88.
CGEM has been the subject of several other research reports. William Blair began coverage on Cullinan Oncology in a report on Monday. They issued an “outperform” rating for the company. HC Wainwright dropped their price objective on Cullinan Oncology from $34.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday. Wedbush began coverage on Cullinan Oncology in a report on Thursday, February 15th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, BTIG Research increased their price objective on Cullinan Oncology from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cullinan Oncology currently has a consensus rating of “Buy” and a consensus price target of $28.75.
Get Our Latest Stock Report on CGEM
Insider Transactions at Cullinan Oncology
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CGEM. Public Employees Retirement System of Ohio bought a new stake in shares of Cullinan Oncology in the 2nd quarter worth $53,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Cullinan Oncology by 352.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,954 shares of the company’s stock worth $50,000 after purchasing an additional 3,859 shares in the last quarter. Point72 Middle East FZE bought a new stake in shares of Cullinan Oncology in the 2nd quarter worth $59,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Cullinan Oncology by 1,331.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,542 shares of the company’s stock worth $59,000 after purchasing an additional 6,085 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Cullinan Oncology by 499.8% in the 2nd quarter. Royal Bank of Canada now owns 8,991 shares of the company’s stock worth $97,000 after purchasing an additional 7,492 shares in the last quarter. Institutional investors own 86.31% of the company’s stock.
Cullinan Oncology Stock Performance
The firm has a market cap of $777.84 million, a P/E ratio of -4.89 and a beta of 0.33. The stock has a fifty day simple moving average of $17.29 and a 200 day simple moving average of $12.60.
Cullinan Oncology (NASDAQ:CGEM – Get Free Report) last posted its earnings results on Thursday, March 14th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.42. Research analysts predict that Cullinan Oncology, Inc. will post -3.6 earnings per share for the current year.
About Cullinan Oncology
Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Read More
- Five stocks we like better than Cullinan Oncology
- Stock Sentiment Analysis: How it Works
- Comprehensive PepsiCo Stock Analysis
- The Significance of Brokerage Rankings in Stock Selection
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is the Hang Seng index?
- Bear Market Funds to Watch This Year
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.